Human papillomavirus infection and the risk of uveitis: a propensity-score-matched electronic health record study Authors: Hui-Chin Chang, Yung-Fang Tu, Ching-Yun Sung, James Lin, Shao-Wei Lo, Yu-Jung Su, Shiu-Jau Chen, Shuo-Yan Gau Published: 2026 ABSTRACT Uveitis is a leading cause of preventable blindness in working-age adults. While herpesviruses are established causes, the potential contribution of human papillomavirus (HPV), a prevalent infection with immunomodulatory properties, remains unexplored. This study aims to investigate whether prior HPV infection is associated with an increased risk of developing uveitis using a large-scale, real-world dataset. In this multicenter, retrospective cohort study, adults aged ≥ 18 years from the TriNetX US Collaborative Network. A total of 460,932 HPV patients and 460,932 propensity score–matched controls without HPV were included after exclusions for malignancy, prior uveitis, or insufficient follow-up. HPV infection was identified by ICD-10-CM codes. Propensity score matching balanced demographics, comorbidities, socioeconomic and behavioral risk factors, and healthcare utilization. Patients were followed for up to 15 years for incident uveitis. Stratified analyses were conducted by age, sex, race, and comorbidities. Sensitivity analyses tested alternative HPV definitions, different washout periods, follow-up horizons, and matching approaches. Incident uveitis defined by ICD-10-CM codes, with hazard ratios (HRs) and 95% confidence intervals (CIs) estimated. HPV infection was associated with an elevated risk of uveitis (HR = 1.30; 95% CI: 1.19–1.42, p < 0.05). Risks persisted across sensitivity analyses, with HRs ranging from 1.23 (95% CI: 1.04–1.47) to 1.46 (95% CI: 1.34–1.59). Subtype analyses showed significant associations with iridocyclitis (HR = 1.27; 95% CI: 1.16–1.39) and unspecified chorioretinal inflammation (HR = 1.49; 95% CI: 1.06–2.09). Stratified analyses demonstrated higher risks among patients aged ≥ 65 years (HR = 1.44; 95% CI: 1.13–1.83), males (HR = 1.63; 95% CI: 1.40–1.89). In patients having both HPV and herpes zoster infection, risk of uveitis was 2.98-fold higher than controls (95% CI, 1.66–5.35). Prior HPV infection was associated with subsequent uveitis-related diagnoses in this large observational study. However, given the reliance on administrative coding, potential diagnostic heterogeneity, and residual confounding, these findings should be interpreted cautiously. Further prospective studies with clinically validated uveitis phenotypes are needed to clarify the nature and clinical relevance of this association.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-51328-x. Introduction Uveitis comprises a spectrum of intra-ocular inflammatory disorders that affect the iris, ciliary body, and choroid1. It is classified as anterior, intermediate, posterior, or panuveitis based on the principal anatomic site of inflammation1. If untreated, the resulting ocular damage may culminate in cataract, glaucoma, macular edema, retinal detachment, and permanent visual loss1. Epidemiologic studies indicate that uveitis accounts for roughly 10–15% of legal blindness in high-income countries, placing it among the five leading causes of vision loss in individuals aged 20 to 50 years2. The etiology of uveitis is multifactorial, encompassing infectious agents, systemic autoimmune or autoinflammatory diseases, masquerade tumors, and idiopathic inflammation, which often requires tailored immunomodulatory treatment strategies1. For example, in Behçet’s disease–associated uveitis, real-world studies have demonstrated substantial variability in treatment response and relapse risk, highlighting the complexity of immune-mediated ocular inflammation3. Among infectious causes, interest has grown in the potential role of viral pathogens as immunologic risk factors of uveitis. For example, herpes simplex virus, varicella-zoster virus, and cytomegalovirus are well-established causes of anterior and posterior uveitis4. Beyond well-established viral etiologies such as herpesviruses, emerging evidence suggests that other viral exposures may also contribute to immune-mediated uveitis. For instance, recent studies have highlighted the potential role of viral infections in the pathogenesis and disease activity of Behçet’s disease–associated uveitis, supporting the concept that viral infections may interact with host immune responses in susceptible individuals5. However, whether other prevalent viruses contribute to uveal inflammation remains incompletely understood. Human papillomavirus (HPV) is a non-enveloped double-stranded DNA virus with marked epithelial tropism and is best known for causing anogenital warts, cervical cancer, and other squamous neoplasms6. Exposure of HPV in the general population is common, as close to 80% of sexually active individuals acquire HPV at some point in their lives7. Beyond its oncogenic potential, persistent HPV infection is capable of evading innate and adaptive immunity, sustaining a chronic pro-inflammatory micro-environment. The virus’s ability to persist in host tissues and modulate immune responses raises the possibility of its contribution to inflammatory ocular diseases such as uveitis through mechanisms such as molecular mimicry. Although HPV DNA has been detected in ocular surface squamous neoplasia and conjunctival tissues8, whether HPV infection predisposes to intra-ocular inflammation has not, to our knowledge, been evaluated in a population-based study. Clarifying this relationship has important public-health implications, as uveitis imposes a heavy burden of morbidity among working-age populations, and HPV infection is potentially modifiable through vaccination. Accordingly, we undertook a nationwide, propensity-score-matched cohort study using real-world data to test the hypothesis that prior HPV infection is associated with an increased risk of incident uveitis. Methods Study framework and data repository This investigation was structured as a multicenter, retrospective cohort analysis, drawing upon information obtained from the TriNetX research platform. TriNetX is an international database that aggregates de-identified electronic health records (EHRs) from a wide network of healthcare organizations. For the present study, the US Collaborative Network within TriNetX was employed. This dataset, previously utilized in epidemiological researches related to ocular diseases9,10, consists of contributions from more than 70 medical institutions and contains longitudinal clinical information for approximately 130 million patients nationwide. Ethics approval and consent to participate This study was performed in accordance with the Declaration of Helsinki and relevant guidelines and regulations. This study was approved by the Institutional Review Board of Chung Shan Medical University Hospital (CS1-25002). Informed consent of participants was waived by the Institutional Review Board. Cohort definition, eligibility criteria and endpoint of interest The study population included adults aged 18 years and older with at least two documented clinical encounters. The exposure cohort was defined as individuals with a diagnosis of HPV infection, identified by International Classification of Diseases, Tenth Revision (ICD-10) diagnostic codes. For these patients, the index date corresponded to the initial recorded diagnosis of HPV between January 1, 2005, and December 31, 2018. The comparison group comprised patients without any history of HPV diagnosis, for whom the index date was designated as the date of a general health examination during the same period. Both cohorts excluded patients with a prior uveitis occurring before or on the index date. Exclusion criteria also encompassed a history of malignancy, death records at any time, or fewer than two encounters during follow-up to ensure data integrity. The endpoint of this study was the development of incident uveitis. Uveitis was defined based on ICD-10-CM diagnostic codes available within the TriNetX database. Specifically, incident uveitis was identified using codes H20 (iridocyclitis), H30.9 (posterior cyclitis), H30.2 (unspecified chorioretinal inflammation), H31.1, H35.06 (retinal vasculitis), and H44.11 (panuveitis), for which similar definitions has been adopted in previous uveitis epidemiology studies11,12. To minimize potential reverse causality, uveitis diagnoses made within three months after the index date were excluded. A full list of diagnostic codes is presented in Table S1 and patient selection flowchart was presented in Fig. 1. Fig. 1Flowchart for participant selection. Flowchart for participant selection. Analytical strategy and statistical considerations To address baseline imbalances between the exposed and comparator groups, propensity score matching was conducted in a 1:1 ratio using nearest-neighbor methodology with a caliper of 0.1. Matching variables included demographic attributes (age, sex, race), clinical comorbidities (e.g., diabetes mellitus, hypertension, hyperlipidemia, Crohn’s disease, ulcerative colitis, viral hepatitis C, herpes simplex, herpes zoster, ankylosing spondylitis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis), healthcare utilization indicators (ambulatory or inpatient encounters), lifestyle-related factors (substance-related mental and behavioral disorders), and socioeconomic parameters (health risks associated with psychosocial and socioeconomic circumstances). Covariate balance was assessed using standardized mean differences, with values < 0.1 indicating acceptable equilibrium. Matching variables were selected a priori based on their potential to confound the association between HPV infection and uveitis13–17. The HPV-uveitis association was assessed by estimating hazard ratios (HRs) and 95% confidence intervals (CIs). Multiple sensitivity analyses were performed to evaluate robustness, including varying the wash-out intervals (12, 24, 36 months) and different follow-up horizons (5, 10, 15 years). Results of these analyses are detailed in Table S2. Subgroup analyses were further performed across strata defined by age (18–64 vs. ≥65 years), sex, race/ethnicity (White, Black, Hispanic, Asian), and comorbidities such as vitamin D deficiency, major depressive disorder, and herpes zoster infection. Results Baseline characteristics of the study participants The baseline characteristics of the study participants are summarized in Table 1, comparing the HPV and control cohorts before and after propensity score matching. Initially, substantial differences were observed between the groups in terms of demographic variables, socioeconomic factors, comorbidities, and healthcare utilization, with SMDs exceeding the 0.1 threshold for multiple variables. Following matching, each cohort included 460,932 individuals, achieving covariate balance across all characteristics as indicated by SMDs below 0.1. Table 1Baseline characteristics.Before matchingAfter matchingaHPV cohortControl cohortSMDHPV cohortControl cohortSMD(n = 466,036)(n = 4,527,904)(n = 460,932)(n = 460,932)Age at indexMean ± SD27.6 ± 15.834.2 ± 20.50.3627.6 ± 15.827.6 ± 15.80SexMale165,227 (35.8)1,976,594 (44.0)0.17165,219 (35.8)164,960 (35.8)0Female286,647 (62.2)2,369,603 (52.8)0.19286,561 (62.2)287,171 (62.3)0Unknown65,043 (14.1)692,245 (15.4)0.0465,035 (14.1)63,970 (13.9)0.01Race, n (%)White295,252 (64.0)2,634,643 (58.7)0.11295,172 (64.0)295,404 (64.1)0Black or African American60,108 (13.0)705,843 (15.7)0.0860,107 (13.0)59,751 (13.0)0Asian16,351 (3.5)212,671 (4.7)0.0616,349 (3.5)16,336 (3.5)0American Indian or Alaska Native1770 (0.4)16,576 (0.4)01770 (0.4)1810 (0.4)0Native Hawaiian or Other Pacific Islander3923 (0.9)29,211 (0.7)0.023923 (0.9)2816 (0.6)0.03Other Race18,579 (4.0)197,355 (4.4)0.0218,576 (4.0)20,845 (4.5)0.02Unknown Race9152 (2.0)142,347 (3.2)0.079152 (2.0)8801 (1.9)0.01Socioeconomic statusPersons with potential health hazards related to socioeconomic and psychosocial circumstances7616 (1.7)34,566 (0.8)0.087589 (1.6)7652 (1.7)0LifestyleMental and behavioral disorders due to psychoactive substance use26,083 (5.7)147,853 (3.3)0.1126,024 (5.6)26,063 (5.7)0Medical Utilization StatusAmbulatory visit310,140 (67.3)2,407,282 (53.6)0.28310,046 (67.3)310,256 (67.3)0Inpatient visit79,150 (17.2)495,219 (11.0)0.1879,067 (17.2)79,392 (17.2)0BMIGreater than 25 kg/m283,940 (18.2)704,879 (15.7)0.0783,880 (18.2)84,263 (18.3)0ComorbiditiesEssential hypertension27,338 (5.9)398,934 (8.9)0.1127,328 (5.9)27,918 (6.1)0.01Hyperlipidemia18,549 (4.0)255,097 (5.7)0.0818,541 (4.0)16,759 (3.6)0.02Diabetes mellitus12,101 (2.6)166,394 (3.7)0.0612,098 (2.6)12,418 (2.7)0Herpes simplex infections6481 (1.4)21,500 (0.5)0.16405 (1.4)6443 (1.4)0Herpes zoster infections2400 (0.5)16,457 (0.4)0.022388 (0.5)2125 (0.5)0.01Viral hepatitis C1360 (0.3)9142 (0.2)0.021357 (0.3)1336 (0.3)0Crohn’s disease1028 (0.2)7593 (0.2)0.011028 (0.2)970 (0.2)0Ulcerative colitis712 (0.2)6434 (0.1)0712 (0.2)632 (0.1)0Systemic lupus erythematosus1027 (0.2)6023 (0.1)0.021026 (0.2)967 (0.2)0Rheumatoid arthritis185 (< 0.1)2579 (0.1)0.01185 (< 0.1)196 (< 0.1)0Ankylosing spondylitis158 (< 0.1)1335 (< 0.1)0158 (< 0.1)126 (< 0.1)0Psoriasis2814 (0.6)14,567 (0.3)0.042796 (0.6)2767 (0.6)0Contact dermatitis27,368 (5.9)86,371 (1.9)0.2127,274 (5.9)27,178 (5.9)0Atopic dermatitis9019 (2.0)27,195 (0.6)0.129001 (2.0)4919 (1.1)0.07Depression27,336 (5.9)163,417 (3.6)0.1127,295 (5.9)22,823 (5.0)0.04Anxiety disorders30,855 (6.7)194,019 (4.3)0.130,817 (6.7)27,139 (5.9)0.03HPV, Human papillomavirus; SMD, standardized mean difference; SD, Standardized difference.a Propensity score matching 1:1 on age at index, sex, race, status of comorbidities (diabetes mellitus, hypertension, hyperlipidemia, Crohn’s disease, ulcerative colitis, contact dermatitis, viral hepatitis C, herpes zoster, herpes simplex, ankylosing spondylitis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis), medical utilization status (ambulatory/inpatient encounter), lifestyle (mental and behavioral disorders due to psychoactive substance use), socioeconomic status (persons with potential health hazards related to socioeconomic and psychosocial circumstances). Table 1Baseline characteristics.Before matchingAfter matchingaHPV cohortControl cohortSMDHPV cohortControl cohortSMD(n = 466,036)(n = 4,527,904)(n = 460,932)(n = 460,932)Age at indexMean ± SD27.6 ± 15.834.2 ± 20.50.3627.6 ± 15.827.6 ± 15.80SexMale165,227 (35.8)1,976,594 (44.0)0.17165,219 (35.8)164,960 (35.8)0Female286,647 (62.2)2,369,603 (52.8)0.19286,561 (62.2)287,171 (62.3)0Unknown65,043 (14.1)692,245 (15.4)0.0465,035 (14.1)63,970 (13.9)0.01Race, n (%)White295,252 (64.0)2,634,643 (58.7)0.11295,172 (64.0)295,404 (64.1)0Black or African American60,108 (13.0)705,843 (15.7)0.0860,107 (13.0)59,751 (13.0)0Asian16,351 (3.5)212,671 (4.7)0.0616,349 (3.5)16,336 (3.5)0American Indian or Alaska Native1770 (0.4)16,576 (0.4)01770 (0.4)1810 (0.4)0Native Hawaiian or Other Pacific Islander3923 (0.9)29,211 (0.7)0.023923 (0.9)2816 (0.6)0.03Other Race18,579 (4.0)197,355 (4.4)0.0218,576 (4.0)20,845 (4.5)0.02Unknown Race9152 (2.0)142,347 (3.2)0.079152 (2.0)8801 (1.9)0.01Socioeconomic statusPersons with potential health hazards related to socioeconomic and psychosocial circumstances7616 (1.7)34,566 (0.8)0.087589 (1.6)7652 (1.7)0LifestyleMental and behavioral disorders due to psychoactive substance use26,083 (5.7)147,853 (3.3)0.1126,024 (5.6)26,063 (5.7)0Medical Utilization StatusAmbulatory visit310,140 (67.3)2,407,282 (53.6)0.28310,046 (67.3)310,256 (67.3)0Inpatient visit79,150 (17.2)495,219 (11.0)0.1879,067 (17.2)79,392 (17.2)0BMIGreater than 25 kg/m283,940 (18.2)704,879 (15.7)0.0783,880 (18.2)84,263 (18.3)0ComorbiditiesEssential hypertension27,338 (5.9)398,934 (8.9)0.1127,328 (5.9)27,918 (6.1)0.01Hyperlipidemia18,549 (4.0)255,097 (5.7)0.0818,541 (4.0)16,759 (3.6)0.02Diabetes mellitus12,101 (2.6)166,394 (3.7)0.0612,098 (2.6)12,418 (2.7)0Herpes simplex infections6481 (1.4)21,500 (0.5)0.16405 (1.4)6443 (1.4)0Herpes zoster infections2400 (0.5)16,457 (0.4)0.022388 (0.5)2125 (0.5)0.01Viral hepatitis C1360 (0.3)9142 (0.2)0.021357 (0.3)1336 (0.3)0Crohn’s disease1028 (0.2)7593 (0.2)0.011028 (0.2)970 (0.2)0Ulcerative colitis712 (0.2)6434 (0.1)0712 (0.2)632 (0.1)0Systemic lupus erythematosus1027 (0.2)6023 (0.1)0.021026 (0.2)967 (0.2)0Rheumatoid arthritis185 (< 0.1)2579 (0.1)0.01185 (< 0.1)196 (< 0.1)0Ankylosing spondylitis158 (< 0.1)1335 (< 0.1)0158 (< 0.1)126 (< 0.1)0Psoriasis2814 (0.6)14,567 (0.3)0.042796 (0.6)2767 (0.6)0Contact dermatitis27,368 (5.9)86,371 (1.9)0.2127,274 (5.9)27,178 (5.9)0Atopic dermatitis9019 (2.0)27,195 (0.6)0.129001 (2.0)4919 (1.1)0.07Depression27,336 (5.9)163,417 (3.6)0.1127,295 (5.9)22,823 (5.0)0.04Anxiety disorders30,855 (6.7)194,019 (4.3)0.130,817 (6.7)27,139 (5.9)0.03HPV, Human papillomavirus; SMD, standardized mean difference; SD, Standardized difference.a Propensity score matching 1:1 on age at index, sex, race, status of comorbidities (diabetes mellitus, hypertension, hyperlipidemia, Crohn’s disease, ulcerative colitis, contact dermatitis, viral hepatitis C, herpes zoster, herpes simplex, ankylosing spondylitis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis), medical utilization status (ambulatory/inpatient encounter), lifestyle (mental and behavioral disorders due to psychoactive substance use), socioeconomic status (persons with potential health hazards related to socioeconomic and psychosocial circumstances). Baseline characteristics. HPV, Human papillomavirus; SMD, standardized mean difference; SD, Standardized difference. a Propensity score matching 1:1 on age at index, sex, race, status of comorbidities (diabetes mellitus, hypertension, hyperlipidemia, Crohn’s disease, ulcerative colitis, contact dermatitis, viral hepatitis C, herpes zoster, herpes simplex, ankylosing spondylitis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis), medical utilization status (ambulatory/inpatient encounter), lifestyle (mental and behavioral disorders due to psychoactive substance use), socioeconomic status (persons with potential health hazards related to socioeconomic and psychosocial circumstances). In the matched cohorts, the mean age at index was 27.6 years, and males comprised 35.8% of each group. The racial distribution was well-balanced, with White individuals representing 64.0%, followed by Black or African American (13.0%) and Asian (3.5%) participants. The proportions of individuals with socioeconomic disadvantage or behavioral disorders due to psychoactive substance use were comparable between groups. Utilization of ambulatory and inpatient care services was identical across cohorts. The prevalence of common comorbidities such as hypertension, hyperlipidemia, diabetes, and herpesvirus infections were similar, with no clinically meaningful differences observed. New-onset uveitis risk The cumulative incidence of uveitis was consistently higher among HPV-infected individuals across the follow-up period (HR: 1.30, 95% CI: 1.19–1.42, log-rank p < 0.05) and the E-value was 1.92 for the HR and 1.66 for the lower confidence bound (Fig. 2). The association remained consistent across multiple sensitivity analyses (Fig. 3). Fig. 2Cumulative probability of uveitis. Cumulative probability of uveitis. Fig. 3Risk of uveitis in patients with HPV infection in different sensitivity models. HPV, human papillomavirus; Detailed information of sensitivity models were reported in Table S2. Risk of uveitis in patients with HPV infection in different sensitivity models. HPV, human papillomavirus; Detailed information of sensitivity models were reported in Table S2. When different proxy-based definitions for HPV infection were applied, the HRs remained elevated: Algorithm 1 (HR: 1.23, 95% CI: 1.04–1.47), Algorithm 2 (HR: 1.45, 95% CI: 1.15–1.83), and Algorithm 3 (HR: 1.40, 95% CI: 1.01–1.94). Varying the wash-out periods before the index date yielded consistent associations with HRs of 1.34 (95% CI: 1.22–1.48), 1.30 (95% CI: 1.18–1.44), and 1.27 (95% CI: 1.15–1.41) for 12-, 24-, and 36-month intervals, respectively. To further address potential confounding by known etiologies of uveitis, we conducted additional analyses excluding patients with major infectious causes (tuberculosis, syphilis, toxoplasmosis) and established immune-mediated conditions (ankylosing spondylitis, Behçet’s disease, and inflammatory bowel disease). The association between HPV infection and incident uveitis remained statistically significant in these restricted analyses (Table S3). Follow-up duration analyses further confirmed the persistence of elevated risk over time. At 5 years, the HR was 1.42 (95% CI: 1.26–1.62), while 10- and 15-year follow-up periods showed HRs of 1.36 (95% CI: 1.24–1.50) and 1.30 (95% CI: 1.19–1.42), respectively. The association was consistent when using more stringent control groups, including cytomegalovirus patients, although the latter comparison did not reach statistical significance (HR: 1.05, 95% CI: 0.70–1.59). Analyses using different matching algorithms yielded comparable findings: Crude model (HR: 1.31, 95% CI: 1.23–1.39), Matching Model 1 (HR: 1.46, 95% CI: 1.34–1.59), and Matching Model 2 (HR: 1.37, 95% CI: 1.25–1.50). Subtype-specific risk of uveitis HPV patients exhibited a significantly higher risk of iridocyclitis (HR 1.27, 95% CI 1.16–1.39) and unspecified chorioretinal inflammation (HR 1.49, 95% CI 1.06–2.09) (Fig. 4). Other subtypes, including posterior cyclitis, retinal vasculitis, and panuveitis, showed elevated point estimates, but these did not reach statistical significance, likely due to smaller sample sizes in these subgroups(Fig. 4). Fig. 4Subcategories of uveitis in patients with HPV infection. HPV, human papillomavirus; Detailed information of sensitivity models were reported in Table S2. Subcategories of uveitis in patients with HPV infection. HPV, human papillomavirus; Detailed information of sensitivity models were reported in Table S2. Stratification analysis Stratified analyses based on demographic and clinical characteristics (Fig. 5) revealed that the association between HPV infection and uveitis remained significant across most subgroups. In age-stratified analyses, patients aged 18–64 years had a 38% higher risk of uveitis (HR 1.38, 95% CI 1.26–1.52), while those aged 65 years and older showed a 44% increased risk (HR 1.44, 95% CI 1.13–1.83). Sex-based stratification revealed a higher risk in males (HR 1.63, 95% CI 1.40–1.89) compared to females (HR 1.36, 95% CI 1.22–1.52). Race-based analyses demonstrated significant associations in Hispanic (HR 1.58, 95% CI 1.22–2.04), White (HR 1.48, 95% CI 1.31–1.67), and Black (HR 1.42, 95% CI 1.20–1.68) populations, but not in Asian patients (HR 0.97, 95% CI 0.59–1.58). Fig. 5Stratification analysis based on age, sex, race and comorbidities. HPV, human papillomavirus; Detailed information of sensitivity models were reported in Table S2. Stratification analysis based on age, sex, race and comorbidities. HPV, human papillomavirus; Detailed information of sensitivity models were reported in Table S2. Comorbidity-based stratification revealed amplified risks. Among individuals with vitamin D deficiency, those with HPV had a 72% higher risk of uveitis (HR: 1.72, 95% CI: 1.39–2.12), while in those with major depressive disorder, the HR was 1.76 (95% CI: 1.31–2.35). In the subgroup with herpes zoster co-infection, the hazard was markedly elevated (HR: 2.98, 95% CI: 1.66–5.35), suggesting a potential synergistic effect. Discussion In this large, multicenter, propensity score–matched cohort study, we found that patients with a history of HPV infection is associated with uveitis. These findings suggest a statistical association between HPV infection and subsequent uveitis-related diagnoses; however, given the limitations in outcome specificity, the results should be interpreted cautiously and may not directly reflect clinically well-defined uveitis entities. Moreover, a causal relationship cannot be established based on this observational study design. HPV infection is known to induce local immune dysregulation, activate the NF-κB pathway through oncoproteins E5, E6, and E7, and increase levels of proinflammatory cytokines such as tumor necrosis factor-α (TNF-α)18,19. These cytokines also play a central role in the pathogenesis of non-infectious uveitis, suggesting plausible biological overlap. Moreover, Th17 responses, along with macrophage dysfunction, are features common to both persistent HPV infection and immune-mediated uveitis20–23. It is possible that HPV, by establishing persistent mucosal or systemic inflammation, may act as an associated factor in susceptible individuals and initiate or amplify ocular autoimmune pathways. Sensitivity analyses reinforced the robustness of our findings. Varying the HPV definition, washout periods (12–36 months), follow-up durations (5–15 years), control group stringency, and matching algorithms all yielded hazard ratios consistently above 1.2. The three-month washout period in the main analysis was selected to minimize the potential for reverse causality and protopathic bias, where early or pre-existing but undiagnosed uveitis may be temporally associated with the initial HPV diagnosis. This approach helps to provide enough lagging period to ensure that the outcome reflects incident uveitis rather than pre-existing or concurrently diagnosed disease. However, there is no golden standard how long should wash-out period being set in epidemiological studies setting uveitis as targeted outcome. Therefore, to strengthen the robustness of this assumption, we conducted sensitivity analyses using extended washout periods (12, 24, and 36 months). Among the various uveitis subtypes, the strongest association was noted for anterior uveitis24(iridocyclitis, HR: 1.27) and unspecified chorioretinal inflammation (HR: 1.49), in line with common phenotypes of autoimmune uveitis25. These observations support the potential for HPV to act as a systemic inflammation associated factor, particularly affecting anterior segment structures. Subgroup analysis revealed that the association between HPV and uveitis persisted across sex, age, and race. Notably, the hazard ratio (HR) was highest among males (HR: 1.63, 95% CI: 1.40–1.89) and individuals aged ≥ 65 years (HR: 1.46, 95% CI: 1.03–2.06), suggesting that age- and sex-related immune differences might contribute the inflammatory consequences of HPV. Race-stratified analyses showed increased risk among White, Black, and Hispanic patients, though statistical significance was not reached for Asians, likely due to small sample size. When stratified by comorbidities, elevated risk was observed in patients with vitamin D deficiency26(HR: 1.41), major depressive disorder27(HR: 1.33), and particularly those with concurrent herpes zoster28(HR: 1.99), consistent with a shared inflammatory or immunosuppressive background. These findings highlight a potentially compounding effect of viral co-infections and immune-modifying conditions on uveitis risk, which may inform risk stratification strategies in clinical settings. Despite the strengths of our study, including a large, diverse population and rigorous matching, certain limitations must be acknowledged. First, as with all observational research using administrative data, the possibility of misclassification bias remains. HPV status was determined by ICD codes, which may underrepresent asymptomatic infections or transient colonization. In addition, the interpretation of uveitis outcomes requires careful consideration. In this study, uveitis and its subtypes were identified using ICD-10-CM diagnostic codes, which, although widely used in large-scale epidemiological studies, may not fully capture clinically adjudicated uveitis entities as defined in subspecialty practice and lack granularity across anatomical subtypes. Certain categories, such as unspecified chorioretinal inflammation, represent heterogeneous groupings that may include inflammatory, infectious, or even misclassified retinal conditions, thereby limiting diagnostic specificity. The inability to distinguish between infectious and noninfectious uveitis may further influence the clinical interpretation of our findings. These entities differ substantially in underlying mechanisms, and combining them into a single outcome may introduce heterogeneity in clinical phenotypes. If HPV-related immune dysregulation primarily contributes to noninfectious or autoimmune uveitis, inclusion of infectious cases may attenuate the observed association. Conversely, shared susceptibility to infections or immune compromise may also partially contribute to the observed relationship. Furthermore, reliance on coding alone without specialist validation or detailed clinical information (e.g., ophthalmologic examination findings or standardized diagnostic criteria) introduces uncertainty regarding whether all identified cases reflect true uveitis as managed in subspecialty settings. In particular, some posterior or chorioretinal diagnoses may represent retinal inflammatory conditions or other ocular disorders that are not strictly classified as uveitis in clinical practice. As such, the outcome definition may encompass a mixture of true uveitis, related inflammatory conditions, and potentially miscoded diagnoses. Second, individuals with coded HPV infection may have different healthcare utilization patterns and more frequent ophthalmic evaluations, potentially leading to differential opportunities for uveitis detection. To mitigate this potential detection bias, baseline healthcare utilization indicators, including prior inpatient and emergency or acute care encounters, were incorporated into the propensity score matching process to balance pre-index healthcare-seeking behavior between groups. After matching, these variables were well balanced, suggesting potentially comparable baseline medical surveillance. However, residual detection bias related to unmeasured differences in ophthalmologic evaluation frequency cannot be fully excluded. Third, residual confounding by unmeasured variables (e.g., HLA-B27 status, immunosuppressant use, sexual behavior, vaccine status) cannot be excluded. Fifth, our analysis could not distinguish between high- vs. low-risk HPV genotypes or assess the role of HPV vaccination in modifying uveitis risk. Fourth, because TriNetX does not permit export of patient-level event times, we could not formally test the proportional hazards assumption (e.g., using Schoenfeld residuals). This is an inherent limitation of using aggregated platform data; however, hazard ratios remain a widely accepted summary measure under these constraints. Conclusions Our findings suggest an association between HPV infection and an increased risk of subsequent uveitis-related diagnoses in a large real-world dataset. However, given the limitations in diagnostic specificity and the potential inclusion of heterogeneous ocular inflammatory conditions, these findings should be interpreted with caution. The results do not establish a clinically specific or causal relationship, and further studies incorporating clinically validated uveitis phenotypes are warranted to clarify this association. In addition, the clinical significance of the observed effect size warrants cautious interpretation. Currently, there is no established minimal clinically important difference for hazard ratios in the context of uveitis risk, and therefore, the magnitude of association observed in this study may not directly translate into clinically meaningful risk stratification. Also, causality cannot be inferred from this study, and further prospective and mechanistic investigations are warranted to clarify the underlying relationship. Further prospective and mechanistic studies are warranted to investigate the causal link, explore strain-specific effects, and determine whether HPV vaccination or antiviral treatments could offer protection against uveitis. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1